You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the ...

Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

TG Therapeutics, Inc ... If both trials are successful, Briumvi will have a similar administration profile to Ocrevus Zunovo in terms of the dosing interval and the time it takes to complete ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...

October 10, 2024--Tredegar Surface Protection, a subsidiary of Tredegar Corporation (NYSE:TG) and a leader in high-quality masking films, is excited to announce the launch of Obsidian Automotive ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...